Clozapine, Fluoxetine, and Benztropine- associated Ileus: Case Report by Pajouhi, Pegah, M.D. (PGY1) & Bourgeois, James A., O.D., M.D.
  
 
Jefferson Journal of Psychiatry, Volume 21, Number 1 ISSN 1935-0783 
© 2007 by the authors 
On the Web:  jdc.jefferson.edu/jeffjpsychiatry 
  
Clozapine, fluoxetine, and benztropine- 
associated ileus: Case report 
 
Pegah Pajouhi, M.D. (PGY1),  James A. Bourgeois, O.D., M.D. 
 
 
ABSTRACT 
Gastrointestinal complications of anticholinergic medications are 
prevalent, potentially life-threatening, and could be more actively 
prevented. We present a case report of an ileus that required surgical 
intervention and developed in the context of clozapine, benztropine, and 
fluoxetine use. The case exemplifies the potential anticholinergic 
toxicities of clozapine and benztropine as well as possible 
pharmacokinetic interactions between fluoxetine, clozapine, and 
benztropine. We discuss ways to minimize the likelihood of 
anticholinergic complications with these medications.    
     
CASE REPORT 
   A 50-year-old schizophrenic man presented with diffuse abdominal pain 
radiating to his flanks, cramping, green emesis, and no bowel movements for 
three days. Outpatient medications included clozapine 200 mg q AM and 
400 mg qhs, benztropine 2 mg bid, and fluoxetine 20 mg q AM. He had a 
history of smoking one and one-half packs of cigarettes daily for 35 years. 
His abdomen was tender in the right lower quadrant and was distended and 
tympanic; bowel sounds were hypoactive. Dilated large bowel loops were 
visible in abdominal plain film and dilated proximal bowel was noted on CT 
scan. His treatment team was unable to resolve the small bowel obstruction 
through bowel rest and decompression. Therefore, exploratory laparotomy 
was performed. Surgery revealed a massively dilated jejunum with a clear 
transition point to decompressed distal bowel; no mechanical source of 
obstruction was identified.  
   He remained off his medications until post-op day 2, at which time he was 
re-started on fluoxetine 20 mg q AM and benztropine 2 mg bid. Clozapine 
200 mg q AM and 400 mg qhs was re-started on post-op day 6.  On post-op 
day 12, the Psychiatric Psychosomatic Medicine (PSM) Service evaluated 
the patient. The PSM Service noted the possibilities of a pharmacokinetic 
clozapine-fluoxetine drug interaction (inhibition of clozapine metabolism by 
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concurrent fluoxetine) and/or a pharmacodynamic clozapine-benztropine 
drug interaction (both agents have significant anticholinergic effects) 
causing or exacerbating the ileus through an anticholinergic mechanism. 
Recommendations to discontinue clozapine and benztropine then to start 
quetiapine 200 mg q AM and 400 mg qhs were implemented. Serum 
clozapine levels were not available. On post-op day 15, the patient reported 
relief of abdominal pain and had reduced abdominal distension. He was 
transferred to a psychiatric facility.   
 
DISCUSSION 
   Clozapine is an atypical antipsychotic that is an antagonist at numerous 
receptors: it is anti-serotonergic (5-HT2, 5-HT3), anti-alpha 1 adrenergic, 
antihistaminic (H1), and antimuscarinic. Its potent preferential blockade of 
dopamine D1 and D4 receptors are likely significant contributors to its 
antipsychotic effects (1). Clozapine produces a dose-dependent increase in 
anticholinergic activity and is primarily hepatically metabolized by P450 
1A2 with additional secondary pathways (2). If used concurrently with 
clozapine, fluoxetine and fluvoxamine increase the risk of developing 
anticholinergic effects; these medications increase clozapine levels by 50% 
and three- to four-fold, respectively, due to inhibition of P450 1A2, 2C9/19, 
2D6, and 3A4. Caffeine consumption may increase clozapine levels (by 
inhibiting P450 1A2), while smoking may decease clozapine levels (by 
induction of P450 1A2) (3). 
   Gastrointestinal effects associated with clozapine include constipation, 
gastric outlet obstruction, prolonged postoperative ileus, and peritonitis with 
bowel perforation; fatalities have been reported (1, 4-10).  The prevalence of 
developing intestinal side effects, ranging from constipation to bowel 
perforation, while taking clozapine has been reported as high as 33% (5-7).  
   The significant anticholinergic effects of benztropine, commonly 
prescribed for EPS, may be especially important when added to the 
anticholinergic effects of clozapine. There have been reported cases of 
intestinal dysmotility attributed to benztropine alone as the primary 
anticholinergic agent (11-13). Minzenberg et al. have produced a useful 
table of the relative anticholinergic potencies of various psychotropic agents 
(14). Their table includes both a “pharmacological index” (based on 
published in vitro studies of muscarinic antagonism) and a “clinical index” 
(based on clinician ratings of anticholinergic side effects). For both indices, 
benztropine is given a value of 1.  Clozapine is among the most 
anticholinergic of the atypical antipsychotics; it has a “pharmacological 
  
 
Jefferson Journal of Psychiatry, Volume 21, Number 1 ISSN 1935-0783 
© 2007 by the authors 
On the Web:  jdc.jefferson.edu/jeffjpsychiatry 
index” of 8 mg clozapine as the anticholinergic equivalent of 1 mg 
benztropine and a “clinical index” of 85 mg clozapine as the anticholinergic 
equivalent of 1 mg benztropine (14). Using the table of Minzenberg et al., 
we find that our patient initially had a combined anticholinergic effect 
totaling 79 benztropine equivalents by the “pharmacological index” and 11 
by the “clinical index”; after clozapine and benztropine were discontinued 
and quetiapine was started, the patient received only 0.8 benztropine 
equivalents by the “pharmacological index” and 2.6 by the “clinical index” 
(14). 
   Long-term, treatment-refractory psychiatric inpatients have additional risk 
factors for developing an ileus. One factor is the compounding effect of a 
long history of high-dose antipsychotic medication that leads to reduced 
bowel motility. A second factor is the reduction of daily physical activity 
levels among patients living in long-term inpatient psychiatric facilities. At 
the Atascadero State Hospital in California, for instance, where 60% of 
patients on clozapine were found to have constipation, the staff implemented 
the Clozapine Constipation Protocol in 1995 (8). The protocol involves 
abdominal imaging and physical assessment prior to starting the medication, 
slow dosage increases (maximum of 100mg/day each week), daily 
documentation of bowel and dietary habits, and input from a dietitian who 
encourages a high-fiber diet, adequate fluid intake, and regular physical 
exercise. Most of the patients on clozapine receive a stool softener or a bulk-
forming laxative, and some are prescribed bethanechol. Taking these 
measures resulted in a significant decline in both the prevalence of 
constipation and the number of patients transferred to the medical unit for 
the treatment of clozapine-induced gastrointestinal dysmotility (8).   
   We offer the following five suggestions to avoid adverse bowel events in 
patients on clozapine and/or benztropine: 1) increased surveillance for bowel 
dysfunction in patient receiving the medications 2) proactive management of 
early bowel dysmotility to prevent serious outcomes 3) avoidance of both 
pharmacodynamic and pharmacokinetic drug-drug interactions that increase 
anticholinergic effects of clozapine (specific avoidance of fluoxetine, 
fluvoxamine, or benztropine with clozapine) 4) use of alternative atypical 
antipsychotic medications with lower degrees of anticholinergic activity in 
patients at higher risk of bowel dysmotility and 5) avoidance of benztropine 
in patients who have had clinical sings of decreased intestinal motility. 
When clozapine is necessary despite a history of clozapine-induced ileus 
(e.g. in patients who are resistant to other medications), clinicians may try 
the following after the patient has fully recovered gastrointestinal motility: 
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1) restart clozapine at a lower dose while continuing to avoid fluoxetine, 
fluvoxamine, and benztropine; or 2) cautiously increase the clozapine dose 
while continuing to avoid these other agents.  When possible, monitoring of 
serum clozapine levels may help. 
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